Pharma Stocks in Review: A Valuation Comparison
In this article, we’ll compare the valuations of Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).
Healthcare
The latest news in the healthcare sector including biotech and telehealth.
A Review of Pharma Stocks’ EPS Growth Rates
In this article, we’ll compare the EPS growth rates of Eli Lilly (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).Delstrigo, Pifeltro, and Merck’s Antiviral Therapy Portfolio
Gilead Sciences’ Atripla, Genvoya, and Stribild generated revenues of $663.0 million, $2.2 billion, and $361.0 million, respectively, in the first half of 2018.Geron: One of the Best-Performing Biotech Stocks in Past Month
Geron (GERN) has been one of the best-performing biotechnology companies in the last month, rising 67.1% since August 10.Electrophysiology Is Expected to Be a Major Asset for BSX in 2018
In the second quarter of 2018, Boston Scientific’s (BSX) electrophysiology business reported revenue of close to $79 million.Analysts Raise Target Prices on UNH Stock in September
Of the 23 analysts covering UNH stock, all of them have “buy” or “strong buy” recommendations for UnitedHealth Group.Do Abiomed’s Valuations Look Attractive?
Abiomed’s (ABMD) revenues rose 36% YoY to ~$180 million in fiscal Q1 2019 compared to $133 million in Q1 2018.Why Invitae Stock Rose 23% in Week Ended August 24
On August 24, Invitae (NVTA) stock closed at $12.56, which represents a ~4.75% growth from its prior day’s close of $11.99.Capital World Investors Sold a Major Position in NBL in Q2
So far in this series, we’ve looked at institutional investments in five major oil-weighted E&P (exploration and production) stocks: ConocoPhillips (COP), EOG Resources (EOG), Occidental Petroleum (OXY), Anadarko Petroleum (APC), and Pioneer Natural Resources (PXD).Understanding Varian Medical Systems’ Business Segments
Revenues from the Oncology Systems segment increased from $564.4 million in fiscal Q3 2017 to $667.2 million in fiscal Q3 2018.Baxter’s Global Business Units Continue to Deliver
Baxter International’s (BAX) global business units delivered strong performances in the second quarter.Here’s What Tesaro’s Valuation Trend Indicates
Tesaro stock has been on a downward trajectory for the past 52 weeks. From a high of $135 on September 5, 2017, it has corrected to $27 in August.What Does Nektar Therapeutics’ Valuation Trend Indicate?
Under its immunology program, Nektar Therapeutics (NKTR) is developing NKTR-358 in collaboration with Eli Lilly and Company (LLY).Analysts Have Mixed Opinions about Ionis
Wall Street analysts estimate that Ionis’s (IONS) Q2 2018 revenues will rise ~30.0% to $135.5 million as compared to $104.2 million in Q2 2017.What Analysts Expect from Haemonetics in Q1 2019
Haemonetics is expected to report 4.3% growth in revenues to $219.9 million during Q1 2019 as compared to $210.9 million during Q1 2018.How Has Noble Energy Stock Been Performing Recently?
Year-over-year, NBL stock has risen ~22.7%, while crude oil prices have surged 46.5% in the same period.Assessing BSX’s Recently Acquired Cryterion Cryoablation Platform
On July 5, Boston Scientific announced its acquisition of Cryterion Medical, which will add Cryterion’s cryoablation platform to BSX’s atrial fibrillation treatment portfolio.Sage Therapeutics’ GABA Receptor–Based Products
On June 12, Sage Therapeutics announced its expedited development plan for SAGE-217.Electrophysiology Business May Be a Solid Growth Driver for BSX
In the first quarter, Boston Scientific (BSX) reported sales of close to $75 million in its electrophysiology business.LUX-DX ICM and WATCHMAN LAAC May Prove Solid Drivers for BSX
Boston Scientific (BSX) is preparing to launch the LUX-DX insertable cardiac monitor (or ICM) in both the United States and Europe.BSX Focuses on Advancing Its Cardiac Rhythm Management Portfolio
Boston Scientific expects the results from its UNTOUCHED trial by 2020.Boston Scientific Expands Its AF Therapy Portfolio with Cryterion
Boston Scientific recently announced its acquisition of the remaining 65% stake in Cryterion Medical for $202 million in an up-front cash payment.How BSX Is Set to Benefit from Its nVision Medical Acquisition
On a reported basis, Boston Scientific’s (BSX) urology and pelvic health sales rose 11.8% YoY (year-over-year) to $293 million in Q1 2018, and 9.2% YoY in constant currency.Endoluminal Surgery May Be Opportunity for Boston Scientific
In June, Boston Scientific (BSX) announced the launch of ORISE, its traction solution used in endoluminal surgery.Exploring Acadia Pharmaceuticals’ Promising Research Pipeline
Acadia Pharmaceuticals’ Nuplazid is commercialized in the US market for the treatment of hallucinations and delusions related to Parkinson’s disease psychosis.What to Expect from Tandem’s Product Pipeline
T:sport is Tandem’s next-generation hardware platform, which is expected to reduce the size of the t:slim pump by 50%.How Pfizer’s Business Segments Have Performed
As discussed, Pfizer’s (PFE) business is divided into two business segments, Innovative Health and Essential Health.Risdiplam: Could It Be PTC Therapeutics’ Future Growth Driver?
In June, PTC Therapeutics (PTCT) presented its updated interim clinical data from the Phase 1 FIREFISH trial.Boston Scientific’s Cardiovascular Segment: Q1 2018 Performance
Boston Scientific’s (BSX) Cardiovascular segment’s net sales increased from $851 million in Q1 2017 to $933 million in Q1 2018.Boston Scientific’s Electrophysiology and Neuromodulation Areas
Worldwide revenues of Boston Scientific’s (BSX) electrophysiology business grew 20% from $64 million in Q1 2017 to $75 million in Q1 2018.What’s the Dividend Yield of the Consumer Non-Cyclical Sector?
The consumer non-cyclical segment recorded a dividend yield of 3%.A Close Look at Baxter International’s Acquisitions
Sales from Baxter International’s (BAX) Acute Therapies rose 22%, from $106 million in Q1 2017 to $129 million in Q1 2018.Verzenio: Major CDK4/6 Inhibitor in the Future
Verzenio has demonstrated double-digit growth in new patient usage in patient segments targeted by the drug’s first two approved indications.How Amgen’s Nplate, Vectibix, and Neupogen Performed in 1Q18
In 1Q18, Amgen’s (AMGN) Nplate revenue grew 16% YoY (year-over-year) to $179 million from $154 million, primarily driven by unit demand.How Celgene Performed in 1Q18
In 1Q18, Celgene’s (CELG) revenue grew 20% year-over-year to $3.5 billion from $3.0 billion, boosted by Revlimid, Pomalyst, and Otezla sales.How Johnson & Johnson’s Key Therapeutic Products Have Performed
Between 1Q17 and 1Q18, Johnson & Johnson’s (JNJ) infectious disease product sales rose 10.8% from $749 million to $830 million.Johnson & Johnson’s Financial Performance
In 1Q18, Johnson & Johnson (JNJ) generated revenue of $20 billion, compared with $17.7 billion in 1Q17.Analyzing Johnson & Johnson’s Geographic Performance
Johnson & Johnson (JNJ) derives revenue from four regions: the United States, Europe, the Western Hemisphere excluding the United States, and the Asia-Pacific region and Africa.Factors that Could Drive Trulicity’s Revenue Growth in 2018
In 1Q18, Trulicity reported $678.3 million in revenues for YoY growth of ~82.0%.Humalog and Basaglar: Major Growth Drivers for Eli Lilly in 2018
The highest-earning asset in Eli Lilly’s (LLY) portfolio is its fast-acting insulin, Humalog, which reported revenues of ~$791.7 million in 1Q18.Analyzing the Market Potential for Amicus’s Galafold
According to Amicus Therapeutics, the annual incidence of the disease in newborn males is estimated to be between 1:40,000 and 1:60,000.Tresiba Could Significantly Drive Novo Nordisk’s Revenue in 2018
In 4Q17, Novo Nordisk’s (NVO) Tresiba generated revenues of 1.9 billion Danish kroner, which is a ~48% YoY growth in local currencies.Cabometyx Could Be Exelixis’s Long-Term Growth Driver
In March 2018, the FDA accepted Exelixis’s (EXEL) supplemental New Drug Application (or sNDA) for Cabometyx.Analysts’ Ratings for Spark Therapeutics and Its Peers in April 2018
Of the 20 analysts covering Spark Therapeutics in April 2018, four have given the stock “strong buy” recommendations.Exploring the Growth Trajectory of Amgen’s Repatha
Amgen (AMGN) is one of the world’s leading biotechnology companies, with a presence in ~100 countries.Pfizer’s Inlyta Expansion Thwarted by Failed Phase III Study
On April 11, 2018, Pfizer (PFE) said its ATLAS trial with Inlyta failed to show improvement in RCC disease-free survival.MitraClip Drives Growth, Gets Reimbursement Approval in Japan
On March 19, 2018, Abbott Laboratories (ABT) announced that it had received reimbursement approval for its MitraClip device in Japan.Understanding FibroGen’s Research Pipeline
Apart from Roxadustat, other products in FibroGen’s pipeline include Pamrevlumab (or FG-3019) and FG-5200.Varian’s HyperArc: Driven by Rising Metastatic Brain Cancer?
Varian Medical Systems’ (VAR) HyperArc is an end-to-end, high-definition, intracranial radiotherapy solution.How Did Novartis’s Established Medicines Segment Perform in 2017?
In 4Q17, Novartis’s (NVS) Galvus generated revenues of $327 million, which is ~10% growth on a year-over-year (or YoY) basis and 5% growth quarter-over-quarter.
